Lorlatinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lorlatinib: From ALK-Positive Non-Small Cell Lung Cancer to Gingival Fibromatosis
One-Sentence Summary
Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor used to treat ALK-positive non-small cell lung cancer (NSCLC). The TxGNN model predicts it may be effective for Gingival Fibromatosis, but this is currently a model-score-only hypothesis, supported by 0 clinical trials and 0 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ALK-positive non-small cell lung cancer (NSCLC) — identified from literature annotations within this evidence pack; no Australian-registered indication text is available because Lorlatinib is not yet marketed in Australia |
| Predicted New Indication | Gingival Fibromatosis |
| TxGNN Prediction Score | 99.81% (network rank 2945) |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for lorlatinib is flagged as a data gap in this evidence pack. Cross-referencing other entries in the same pack, lorlatinib is consistently described as a potent, brain-penetrant, third-generation ALK/ROS1 tyrosine kinase inhibitor, with its efficacy in ALK-positive advanced NSCLC well established through Phase III trials (e.g. the CROWN study).
Gingival fibromatosis is a benign, non-malignant overgrowth of gum connective tissue, most often hereditary or induced by unrelated drug classes (e.g. anticonvulsants, calcineurin inhibitors, calcium channel blockers). No biological pathway linking ALK/ROS1 inhibition to gingival connective-tissue overgrowth is described anywhere in this evidence pack.
The evidence pack’s own annotation for this candidate is explicit: “no clinical evidence, no known mechanistic link — this reflects the TxGNN model score alone, with no supporting trial or literature.” This ranking should be treated purely as an exploratory model hypothesis, not as a mechanistically grounded lead.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Lorlatinib is not currently registered on the ARTG (Australian Register of Therapeutic Goods); no product licence entries are on file.
Cytotoxicity
Lorlatinib is an antineoplastic agent (ALK/ROS1-targeted therapy used in NSCLC), so this section is included.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (third-generation ALK/ROS1 tyrosine kinase inhibitor) — not conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions (no myelosuppression data identified in this evidence pack) |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Based on adverse-event literature in this pack: lipid panel (hypercholesterolaemia/hypertriglyceridaemia reported), weight and metabolic monitoring, mood/CNS assessment, and respiratory monitoring (case reports of ARDS and pulmonary toxicity when combined with anti-GD2 antibody therapy) |
| Handling Protection | Please refer to the Product Information (PI) warnings and precautions |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (gingival fibromatosis) has no supporting clinical trials or literature and no described mechanistic rationale — it is an L5, model-score-only signal. Lorlatinib also holds no ARTG registration in Australia, and the TFDA-equivalent warnings/contraindications needed for a Stage 1 safety review are a Blocking data gap (DG001).
To proceed, the following is needed:
- TFDA/TGA-equivalent Product Information — warnings and contraindications (DG001, Blocking)
- Confirmed mechanism-of-action documentation for lorlatinib (DG002, High)
- Preclinical or case-level evidence specifically linking ALK/ROS1 inhibition to gingival fibromatosis pathophysiology
- Monitoring of ARTG registration status, as the drug is currently not marketed in Australia
Note: other candidates in this ranked batch (e.g. lung hilum carcinoma, L3) carry somewhat more evidence, though only a single case report and with data-quality caveats noted in the source data; none currently justify a stronger decision than Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.